Aurinia Pharmaceuticals Inc. (AUPH) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 11 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for AUPH is $15.50, representing a -3.5% downside from the current price of $16.07. Price targets range from a low of $15.00 to a high of $16.00.
